NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC · 20 Sep
The Screen · Healthcare · Medical Instruments & Supplies
Becton Dickinson
BDX · a US exchange · USD · Market cap $49.0B · 60,000 employees
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laborat…
FAIL · Does not pass the screen
179.80 USD
At the last full screen 2026-09-09
Screened 2026-09-09 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 179.80 against the desk's fair-value range, base estimate 225.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price179.80 USD
Fair value225.00
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-08-23Read Markup187.62-4.2% to today
2026-07-02Read Distribution151.16+18.9% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Becton Dickinson holds its Markup at $179.80. The statistical read favours the buyers, held for 56 days.
As held on the ledger · 2026-09-09
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 56 days
Price at the screen
$179.80
Valuation
31.11 trailing · 13.53 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.28
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.67%
Below 33%
Interest-bearing debt is 34.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.01%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
6.57%
Below 49%
Money owed to the company is 6.6% of assets, under the 49% limit.
Pass
Revenue purity
0.17%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 25% discount to our $225.00 fair value, narrow competitive moat, 5.40% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 25.1% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +10% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medical giant fails where numbers look fine
Every time a hospital stocks syringes or a lab processes samples, Becton Dickinson sits in the background supplying the kit. The shares trade at 158 dollars against a fair value near 219, and forward earnings sit at just 11.8 times. Yet none of that moves the needle for us.
We pass because the business fails our ethical screen on debt ratio. Revenue growth runs at 5 percent, profit margins sit at 5 percent and return on equity reaches only 7 percent with a narrow moat. Analyst targets cluster around 175 dollars on a buy rating, but the ethical bar is non negotiable.
The low multiple reflects modest growth and thin returns rather than hidden value. Debt levels add further caution in a sector where steady cash flow should not require heavy leverage. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BDX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-23Markup · changed$187.62+18.6%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183.
2026-07-22Distribution$158.17+4.6%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183.
2026-07-18Distribution$151.16+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183.
2026-07-03Distribution$151.16+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$151.16Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
